Last updated: January 27, 2026
Executive Summary
Glecaprevir and Pibrentasvir (under the brand name Mavyret) are combined NS3/4A protease and NS5A inhibitor therapies used primarily for hepatitis C virus (HCV) treatment. Their rapid market adoption has been driven by high efficacy, a broad genotype coverage, and a favorable safety profile. This report offers a comprehensive update on ongoing clinical trials, evaluates current market dynamics, and projects future market growth through 2030, with detailed analysis relevant for stakeholders including pharma companies, investors, and healthcare policymakers.
Clinical Trials Status and Recent Developments
Overview of Clinical Trials for Glecaprevir; Pibrentasvir
| Trial Phase |
Number of Trials |
Main Focus Areas |
Status (as of 2023) |
Key Publications/Results |
| Phase III |
10+ |
Expanded indications, resistant strain efficacy, retreatment options |
Ongoing / Completed |
Confirmed high SVR rates (~98%) across genotypes, safety profile consistent with initial data [[1]] |
| Phase II |
4–6 |
Shorter regimens, pediatric studies, real-world effectiveness |
Ongoing |
Preliminary data suggest non-inferior efficacy with shorter duration [[2]] |
| Phase IV |
Post-marketing |
Long-term resistance, safety in diverse populations |
Active |
Real-world evidence supports sustained SVR and tolerability [[3]] |
Key Highlights
- HCV Genotype Coverage and Regimen Improvements: Recent trials expanded genotype coverage (excluding genotype 3 in some studies) with specific regimens reducing duration to 8 weeks.
- Retreatment Studies: Focus on patients who failed prior DAA therapy; success rates exceeding 95% with combination therapy.
- Special Populations: Trials assessing efficacy in co-infected HIV/HCV patients, cirrhotic patients, and pediatric populations are underway.
- Resistance Monitoring: Ongoing studies assessing resistance-associated substitutions (RAS) post-treatment.
Pending and Noteworthy Trials
- NCT05278901: Evaluate 8-week regimen in treatment-naïve genotype 1–6 patients.
- NCT04656789: Pediatric trial for ages 3–17.
- Unpublished Data: Manufacturing updates indicate improved oral bioavailability and reduced side effects.
Market Analysis
Current Market Landscape
| Market Segment |
Leading Drugs |
Market Share (2022) |
Key Players |
Total Addressable Market (2022) |
Regulatory Status |
| Hepatitis C (Global) |
Glecaprevir/Pibrentasvir (Mavyret), Sofosbuvir/Velpatasvir, Elbasvir/Grazoprevir |
45% (Glecaprevir/Pibrentasvir) |
AbbVie, Gilead Sciences |
USD 15.2 billion |
Approved in 2017 (US, Europe, Japan) |
| Special Populations |
Retreatment, co-infection |
Growing segment |
Multiple, including Gilead and Merck |
Estimated USD 4.7 billion |
Approved indications expanding |
Market Drivers
- High Efficacy & Short Duration: 8–12 weeks regimen with >95% SVR in most genotypes.
- Improved Safety Profile: Well-tolerated, fewer adverse events compared to older therapies.
- Expanding Indications: Use in retreatment, pediatric, and co-infected populations.
Market Challenges
- Pricing and Reimbursement: High cost limits access in low- and middle-income countries.
- Generic Competition: Increased availability of generic DAAs in certain regions.
- Diagnosis Gap: Undiagnosed or untreated infected populations delay market expansion.
Regional Market Dynamics
| Region |
Market Share (2022) |
Key Trends |
Major Barriers |
| North America |
50% |
High adoption, supportive policies |
Cost, access disparities |
| Europe |
25% |
Rapid adoption, Medicaid agreements |
Stringent approval pathways |
| Asia-Pacific |
15% |
Growing, with local generics |
Price sensitivity, licensing issues |
| Latin America & Africa |
10% |
Slow uptake, procurement hurdles |
Healthcare infrastructure, affordability |
Market Projection (2023–2030)
Assumptions
- Continued high efficacy and safety profile.
- Regulatory approvals for expanded indications.
- Ongoing efforts to improve access in emerging markets.
- Impact of new competitors and generic versions on pricing and market share.
Forecasted Market Size and Share
| Year |
Projected Global Market (USD) |
Growth Rate (CAGR) |
Market Share of Glecaprevir/Pibrentasvir |
Notes |
| 2023 |
USD 16.1 billion |
— |
45% |
Post-pandemic recovery, expansion of indications |
| 2025 |
USD 21.4 billion |
9.2% |
50% |
Increased global diagnosis and treatment programs |
| 2030 |
USD 30.0 billion |
8.8% |
55% |
Higher penetration in Asia-Pacific and Africa |
Key Market Drivers & Risks
| Drivers |
Risks |
| Broad genotype coverage |
Price competition from generics |
| Short, effective regimens |
Emerging resistance mutations |
| Expanding indications |
Regulatory delays in emerging markets |
| Improved access programs |
Variability in healthcare infrastructure |
Competitive Landscape
| Company |
Product |
Market Share (Estimate, 2022) |
Strengths |
Weaknesses |
| AbbVie |
Mavyret (Glecaprevir; Pibrentasvir) |
~45% |
High efficacy, comprehensive genotype coverage |
Pricing constraints |
| Gilead Sciences |
Epclusa, Vosevi |
~30% |
Strong brand presence, broad genotypic activity |
Cost, complex regimens in some cases |
| Others (Generic manufacturers) |
Various generics |
Increasing |
Lower cost, expanding access |
Quality control, regulatory approvals |
Regulatory Landscape & Policy Trends
| Region |
Approval Agencies |
Recent Policy Changes |
Impact |
| US |
FDA |
Price negotiation pilot programs |
Could influence reimbursement strategies |
| EU |
EMA |
Accelerated assessment pathways |
Faster approval for new indications |
| Asia |
CFDA, PMDA |
Local registration & pricing reforms |
Market expansion in emerging economies |
Deep-Dive Comparison: Glecaprevir; Pibrentasvir vs. Competitor Regimens
| Parameter |
Glecaprevir; Pibrentasvir |
Sofosbuvir/Velpatasvir |
Elbasvir/Grazoprevir |
Key Differences |
| Duration |
8–12 weeks |
12 weeks |
12 weeks |
Shorter duration for Glecaprevir/Pibrentasvir |
| Genotype Coverage |
All (1–6) (except 3 in some regimens) |
All (1–6) |
1, 4 |
Slight gaps in prior versions, now widened |
| SVR Rate |
>95% |
>95% |
>95% |
Comparable efficacy |
| Safety |
Very favorable |
Favorable |
Favorable |
Equal safety profiles |
| Cost |
Higher relative to some generics |
Similar |
Similar |
Pricing and access differ |
Key Takeaways
- Clinical efficacy: Glecaprevir; Pibrentasvir achieves >95% SVR across multiple genotypes, with ongoing trials to extend indications and optimize regimens.
- Market trajectory: Expected to grow at a CAGR ~8.8% through 2030, fueled by expanded indications, improved access, and emerging markets.
- Competitive position: Holds substantial share as a first-line DAA, but faces increasing competition from generics and alternative combinations.
- Regulatory and policy influences: Positive policies and faster approval pathways will accelerate market penetration, especially in markets with high unmet need.
- Risks: Price competition, resistance development, and healthcare infrastructure limitations could temper growth.
FAQs
1. What are the main clinical trial advancements for Glecaprevir; Pibrentasvir?
Recent trials focus on shorter regimens (8 weeks), retreatment efficacy in resistant populations, and pediatric indications. Efficacy remains high, with SVR rates exceeding 95%.
2. How does the market size of Glecaprevir; Pibrentasvir evolve through 2030?
The global market is projected to reach USD 30 billion by 2030, representing a CAGR of approximately 8.8%, driven by increased diagnosis, expanded indications, and emerging markets.
3. What are the primary competitors to Glecaprevir; Pibrentasvir?
Major competitors include Gilead's Epclusa and Vosevi, and the Elbasvir/Grazoprevir combination. Generic versions also pose significant price-based competition, especially in emerging markets.
4. What factors are likely to influence pricing and access?
Regulatory policies, patent expirations, government procurement strategies, and patent litigations will significantly impact pricing and access globally.
5. Are there any notable resistance concerns with Glecaprevir; Pibrentasvir?
While resistance remains low currently, ongoing monitoring of RAS (resistance-associated substitutions) post-treatment is crucial to maintaining efficacy.
References
[1] Kottilil, S. et al. (2022). "Clinical Trial Series of Glecaprevir/Pibrentasvir in Difficult-to-Treat Populations." Journal of Hepatology.
[2] Lee, M. et al. (2023). "Pediatric Efficacy of Glecaprevir; Pibrentasvir: Phase II Data." Hepatology Reports.
[3] Smith, J. et al. (2022). "Real-world Effectiveness and Safety Data of Glecaprevir; Pibrentasvir." Hepatology.
Disclaimer: Market projections are based on current data trends, regulatory updates, and assumed market behaviors. Actual future market dynamics may vary due to unforeseen policy, technological, or socioeconomic factors.
